IMUX
Immunic, Inc. · Healthcare
1.22
4.27%(+0.05)
Market OpenLast Updated: — ET
52W L: $0.5152W H: $1.51
$1.21
CHG+0.00 (+0.00%)
H$1.57
L$1.02
VOL52M
IMUX (1h)
Immunic, Inc. · Healthcare
11:05am: 'Wait and see' Axel Rudolph, chief technical analyst at IG, notes that traders are largely adopting a wait‑and‑see approach as Trump’s deadline for...
NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on March 27, 2026, informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. According to the Notice, Immunic has regained compliance with the minimum bid price requirement, because the closing bid price of the Company's common stock was at $1.00 per share or greater for at least 20 consecutive business days, satisfying the Nasdaq requirement on March 26, 2026.
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to its board of directors, as the company advances its multiple sclerosis program through late-stage development. Congleton brings nearly four decades of experience in the biopharmaceutical industry, with a background spanning drug development, commercialization, and executive leadership, according to Immunic.
– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis – – Served on Original Team Responsible for the Launch of Copaxone® in the United States – NEW YORK, March 31, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to its Board of Directors, effective March 27, 2026. Mr. Congleton has a strong track record of building and leading biopharmaceutical organizations and advancing innovative therapies.
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to its board of directors, as the...
On March 24, 2026, choppy, oil-driven trading and fresh AI disruption fears pressured major U.S. indexes.
Congleton Jon
director:
0 SH @ $0.00
2026-03-27
BVF PARTNERS L P/IL
director, other: See Explanation of Responses
0 SH @ $0.00
2026-02-17
BVF PARTNERS L P/IL
director, other: See Explanation of Responses
0 SH @ $0.00
2026-02-17
BVF PARTNERS L P/IL
director, other: See Explanation of Responses
0 SH @ $0.00
2026-02-17
BVF PARTNERS L P/IL
director, other: See Explanation of Responses
3,202,262 SH @ $0.00
2026-02-17
BVF PARTNERS L P/IL
director, other: See Explanation of Responses
3,202,262 SH @ $0.00
2026-02-17
Nagel Robert Thorvald
director:
0 SH @ $0.00
2026-02-17
Whaley Glenn
officer: Chief Financial Officer
560,000 SH @ $0.77
2025-07-16